A Multicentre Study of 2019 Novel Coronavirus Disease Outcomes of Cancer Patients in Wuhan, China

Hong-Yan Zhang; Lin-Wei Wang; Yuan-Yuan Chen; Xiao-Kun Shen; Qun Wang; You-Qin Yan; Yi Yu; Qiuji Wu; Xinghuan Wang; Ya-Hua Zhong; Melvin Chua Lee Kiang; Cong-Hua Xie

In this multicentre retrospective study, we reported the largest cohort of cancer patients with of COVID-19 patients develop ARDS, 7 while the incidence rate of ARDS in our cancer cohort was 16.42%. The CFR rate of cancer patients infected by SARS-CoV-2 was higher than that of the overall population. According to the situation report from the WHO, 153517 cases of COVID-19 had been confirmed all around the world up to Mar 15, 2020, with a CFR rate of approximately 3.7%. 5 In contrast, the crude CFR in our cohort was about 26.9%. Our findings provided evidence that cancer patients with COVID-19 could have a poorer outcome, which was consistent with the previous study. 6 In this study, the CFR of patients receiving ongoing anticancer treatment recently (39.1%, 9/23) was higher than those who were merely on follow-up post-cancer treatment. in the routine follow-up phase after radical treatment (20.5%, 9/44). Furthermore, we observed a tendency that patients at the follow-up phase may have a better prognosis than those under treatment (Figure 1, P=0.095) . Those results provide further evidence to demonstrate that patients receiving ongoing anticancer treatment recently have a poorer prognosis than those patients at follow-up phase. It may a result of immune compromising effect led by anticancer treatments. [12] [13] [14] Noteworthy, this study showed that lung cancer was the most common cancer type (accounted for 22.4%), which may have higher susceptibility SARS-CoV-2 infection than other type cancers. There may be two main reasons: (1) lung cancer accounts for a large . CC-BY-NC-ND 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity.